(NASDAQ: VYNE) Vyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Vyne Therapeutics's earnings in 2025 is -$38,545,000.On average, 6 Wall Street analysts forecast VYNE's earnings for 2025 to be -$18,013,915, with the lowest VYNE earnings forecast at -$22,216,822, and the highest VYNE earnings forecast at -$15,512,548. On average, 5 Wall Street analysts forecast VYNE's earnings for 2026 to be -$21,954,459, with the lowest VYNE earnings forecast at -$27,458,994, and the highest VYNE earnings forecast at -$15,780,006.
In 2027, VYNE is forecast to generate -$42,869,654 in earnings, with the lowest earnings forecast at -$41,188,491 and the highest earnings forecast at -$44,130,526.